Ratings AVITA Medical, Inc.

Equities

RCEL

US05380C1027

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
8.63 ^USD	+6.54%		+6.02%	-37.10%

May. 22	Transcript : AVITA Medical, Inc. - Special Call
May. 14	Cantor Fitzgerald Trims Price Target on Avita Medical to $21 From $22, Maintains Overweight Rating	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past four months, analysts' average price target has been revised downwards significantly.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
AVITA MEDICAL, INC.	-37.10%	223M	C
MODERNA, INC.	+54.05%	58.71B	B-
IQVIA HOLDINGS INC.	-2.02%	41.31B	B
LONZA GROUP AG	+40.01%	39.2B	A
CELLTRION, INC.	-10.22%	27.4B	C
ICON PUBLIC LIMITED COMPANY	+13.42%	26.55B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.98B	B
BIO-TECHNE CORPORATION	+2.89%	12.51B	B+
UNITED THERAPEUTICS CORPORATION	+22.40%	11.94B	B+
MEDPACE HOLDINGS, INC.	+27.49%	12.08B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders